💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Levodopa

CHEMBL1009 Phase 4 Approuvé Small molecule
Half-Life
1.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
197.2 g/mol
LogP
-2.7
Phase
4

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

Masse moléculaire

197,1880 g/mol

LogP

-2,70

TPSA

104,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Age-Related Macular Degeneration Pain Management Asthma Alzheimer's Disease Parkinson's Disease Schizophrenia Generalized Anxiety Disorder Stroke Type 2 Diabetes Major Depressive Disorder Chronic Pain

Classes de médicaments

N — N - Nervous System

Mécanisme d'action

Metabolic precursor of dopamine that crosses the BBB.

Pharmacokinetics (PK)

Half-Life 1.5 hours

Pharmacodynamics (PD)

Mécanisme

Metabolic precursor of dopamine that crosses the BBB.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H11NO4

                    

                    
                    

                        
HBD / HBA

                        
4 / 5

                    

                    
                    

                        
Liaisons Rotatives

                        
3

                    

                    
                    
                    

                        
Atomes Lourds

                        
14

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            DRD2 (Dopamine D2 Receptor)
                            Agonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Levodopa + Quetiapine
                            
                        

                        
                        
Quetiapine, a D2 receptor antagonist, pharmacodynamically opposes levodopa's dopaminergic effect, worsening Parkinson's disease motor symptoms.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Levodopa + Aripiprazole
                            
                        

                        
                        
Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Levodopa + Carbamazepine
                            
                        

                        
                        
Carbamazepine may reduce levodopa efficacy through enzyme induction and pharmacodynamic antagonism, potentially worsening Parkinson's disease control.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Metabolic precursor of dopamine that crosses the BBB.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Levodopa: Half-life: 1.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Levodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1009.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6047.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.